[go: up one dir, main page]

MA29335B1 - Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur - Google Patents

Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur

Info

Publication number
MA29335B1
MA29335B1 MA30225A MA30225A MA29335B1 MA 29335 B1 MA29335 B1 MA 29335B1 MA 30225 A MA30225 A MA 30225A MA 30225 A MA30225 A MA 30225A MA 29335 B1 MA29335 B1 MA 29335B1
Authority
MA
Morocco
Prior art keywords
pain
sulfonylaminomethyl
treatment
derivatives useful
cyclopropanecarboxamide
Prior art date
Application number
MA30225A
Other languages
English (en)
Inventor
Takeshi Hanazawa
Misato Hirano
Tadashi Inoue
Satoshi Nagayama
Kazunari Nakao
Yuji Shishido
Hirotaka Tanaka
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA29335B1 publication Critical patent/MA29335B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/28—Unsaturated compounds polycyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/40—Unsaturated compounds containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'INVENTION CONCERNE UN COMPOSÉ REPRÉSENTÉ PAR LA FORMULE (I) OU UN SEL OU UN SOLVAT DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE. CES COMPOSÉS SONT UTILISÉS POUR TRAITER DES ÉTATS PATHOLOGIQUES ENTRAÎNÉS PAR LA SURACTIVATION DU RÉCEPTEUR VR1, TELS QU'UNE DOULEUR OU ANALOGUE CHEZ UN MAMMIFÈRE. L'INVENTION CONCERNE ÉGALEMENT UNE COMPOSITION PHARMACEUTIQUE COMPRENANT LES COMPOSÉS PRÉCITÉS.
MA30225A 2005-03-17 2007-09-17 Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur MA29335B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66337405P 2005-03-17 2005-03-17
US69980005P 2005-07-15 2005-07-15
US73365105P 2005-11-04 2005-11-04

Publications (1)

Publication Number Publication Date
MA29335B1 true MA29335B1 (fr) 2008-03-03

Family

ID=36570286

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30225A MA29335B1 (fr) 2005-03-17 2007-09-17 Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur

Country Status (25)

Country Link
US (2) US7622589B2 (fr)
EP (1) EP1861359B1 (fr)
JP (1) JP4521463B2 (fr)
KR (1) KR100927915B1 (fr)
CN (1) CN101160285A (fr)
AP (1) AP2007004157A0 (fr)
AR (1) AR055878A1 (fr)
AU (1) AU2006224295A1 (fr)
BR (1) BRPI0608436A2 (fr)
CA (1) CA2601508C (fr)
CR (1) CR9375A (fr)
DO (1) DOP2006000063A (fr)
EA (1) EA200701745A1 (fr)
GT (1) GT200600114A (fr)
IL (1) IL185546A0 (fr)
MA (1) MA29335B1 (fr)
MX (1) MX2007011498A (fr)
NL (1) NL1031385C2 (fr)
NO (1) NO20075312L (fr)
PE (1) PE20061150A1 (fr)
TN (1) TNSN07349A1 (fr)
TW (1) TW200716528A (fr)
UY (1) UY29421A1 (fr)
WO (1) WO2006097817A1 (fr)
ZA (1) ZA200707531B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
JP4173909B1 (ja) * 2005-04-28 2008-10-29 ファイザー・リミテッド アミノ酸誘導体
WO2007129188A1 (fr) * 2006-05-10 2007-11-15 Pfizer Japan Inc. Composé de cyclopropanecarboxamide
KR101410318B1 (ko) 2006-07-27 2014-06-27 (주)아모레퍼시픽 바닐로이드 수용체 길항제로서의 신규 화합물, 그의 이성질체, 또는 약제학적으로 허용가능한 그의 염, 및 이를함유하는 약제학적 조성물
EP2125797B1 (fr) 2007-03-16 2014-01-15 Actelion Pharmaceuticals Ltd. Dérivés d'amino-pyridine comme agonistes du récepteur s1p1/edg1
CN102648198B (zh) 2007-08-17 2015-04-01 埃科特莱茵药品有限公司 作为s1p1/edg1受体调节剂的吡啶衍生物
CA2703220A1 (fr) * 2007-11-13 2009-05-22 Pfizer Global Research And Development Derives amide a titre de ligands des canaux ioniques et compositions pharmaceutiques et procedes d'utilisation correspondants
EP2238105B1 (fr) 2008-01-28 2014-04-16 Amorepacific Corporation Nouveaux composés, isomère ou sels pharmaceutiquement acceptables de ces derniers, utilisés comme antagonistes du récepteur vanilloïde, et compositions pharmaceutiques les contenant
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
RU2499592C2 (ru) 2008-04-21 2013-11-27 Отономи, Инк. Фармацевтическая композиция для лечения ушных заболеваний
CN102137851B (zh) 2008-07-02 2014-08-27 株式会社爱茉莉太平洋 作为香草素受体拮抗剂的化合物、其异构体或其药学可接受的盐以及包含它们的药物组合物
CN102105133B (zh) 2008-07-21 2015-06-17 奥德纳米有限公司 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法
KR101367057B1 (ko) 2009-03-17 2014-02-25 (주)아모레퍼시픽 피부 자극 완화용 조성물
WO2010056044A2 (fr) * 2008-11-11 2010-05-20 (주)아모레퍼시픽 Nouveau composé faisant fonction d'antagoniste du récepteur vanilloïde, isomère ou sel pharmaceutiquement acceptable dudit composé, et composition pharmaceutique le contenant
KR101252335B1 (ko) 2009-07-16 2013-04-08 (주)아모레퍼시픽 피부 노화 방지용 조성물
US9101616B2 (en) * 2009-05-29 2015-08-11 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
US8497271B2 (en) * 2009-10-07 2013-07-30 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
WO2012009698A1 (fr) 2010-07-16 2012-01-19 Abbott Laboratories Ligands phosphine pour réactions catalytiques
MX2013000623A (es) * 2010-07-16 2013-06-13 Abbvie Inc Proceso para la preparación de compuestos antivirales.
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
UA111746C2 (uk) * 2011-07-08 2016-06-10 Х. Луннбек А/С Позитивні алостеричні модулятори нікотинового рецептора ацетилхоліну
HRP20180913T1 (hr) * 2011-07-08 2018-07-27 H. Lundbeck A/S Pozitivni alosterni modulatori receptora nikotinskog acetilkolina
US10479763B2 (en) 2015-02-17 2019-11-19 Amorepacific Corporation Chiral resolution method of N-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives
EP3404021A4 (fr) 2016-01-12 2019-09-11 Nippon Chemiphar Co., Ltd. Inhibiteur du canal calcique de type t tension-dépendant
EP3478269A4 (fr) 2016-06-29 2020-04-08 Otonomy, Inc. Formulations otiques à base de triglycérides et leurs utilisations
KR102599958B1 (ko) * 2016-09-28 2023-11-09 (주)아모레퍼시픽 (r)-n-[4-(1-아미노-에틸)-2,6-다이플루오로-페닐]-메테인설폰아마이드의 제조방법
JP7140332B2 (ja) 2017-01-23 2022-09-21 日本ケミファ株式会社 電位依存性ｔ型カルシウムチャネル阻害剤
WO2022087634A1 (fr) * 2020-10-23 2022-04-28 Nimbus Clotho, Inc. Inhibiteurs de ctps1 et leurs utilisations
WO2023054626A1 (fr) * 2021-09-30 2023-04-06 住友ファーマ株式会社 Dérivé de cyclopropanamide
CN114544845A (zh) * 2022-01-07 2022-05-27 广州白云山医药集团股份有限公司白云山制药总厂 一种盐酸达泊西汀中r异构体的测定方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1108213B (de) 1959-02-28 1961-06-08 Frantisek Sorm Dr Ing Verfahren zur Herstellung von 2, 2-Dimethyl-3-phenylcyclopropan-carbonsaeuren
NL128365C (fr) 1963-11-05
US3526634A (en) 1967-10-30 1970-09-01 Takeda Chemical Industries Ltd Alkylbenzoylcarbinol esters
US4083336A (en) 1971-08-10 1978-04-11 Texas Instruments Incorporated Condition responsive control device
JPS565435A (en) * 1979-06-26 1981-01-20 Nissan Chem Ind Ltd Trans-2,2-dimethyl-3- p-substituted phenyl -cyclopropane- carboxylic acid and its preparation
DE3220730A1 (de) 1982-06-02 1983-12-08 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 2,2-dimethyl-3-aryl-cyclopropan-carbonsaeuren (carbonsaeureestern), neue zwischenprodukte hierfuer und verfahren zu deren herstellung
DE3582728D1 (de) 1985-01-17 1991-06-06 Ici Plc Tertiaere aminoverbindungen.
US4786646A (en) 1987-07-10 1988-11-22 Hoffmann-La Roche Inc. Cyclopropylpropenamides
US4927826A (en) 1987-07-10 1990-05-22 Hoffman-La Roche Inc. Cycloproylpropenamides useful as platelet activing factor (PAF) antagonists
DE3815728A1 (de) 1988-05-07 1989-11-16 Bayer Ag Stereoisomere von n-(r)-(1-aryl-ethyl)-1-alkyl-2,2-dichlor- cyclopropancarbonsaeureamiden
DE3823521A1 (de) 1988-07-12 1990-02-15 Basf Ag Cyclopropancarboxamide, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von schaedlingen
DE3824788A1 (de) 1988-07-21 1990-02-22 Basf Ag Cyclopropancarboxamide, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von schaedlingen
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5286736A (en) 1990-11-22 1994-02-15 Dr. Karl Thomae Gmbh Pyridyl compounds and pharmaceutical compositions containing these compounds
JPH05262698A (ja) 1992-03-24 1993-10-12 Dainippon Ink & Chem Inc 光学活性トリフルオロメチルシクロプロパン誘導体、その合成中間体、それを含む液晶組成物及び液晶表示素子
GB9220137D0 (en) 1992-09-23 1992-11-04 Pfizer Ltd Therapeutic agents
GB9311282D0 (en) 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd New compositions of matter
ZA961314B (en) 1995-02-21 1996-08-27 Hoechst Ag Substituted benzenesulfonylureas and -thioreas processes for their preparation their use for the production of pharmaceutical preparations and medicaments containing them
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
DE19624704A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalkansäureamide
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
MXPA00004940A (es) 1997-11-21 2002-10-17 Nps Pharma Inc Antagonistas de receptor de glutamato metabotropico para tratar enfermedades del sistema nervioso central.
DE19756261A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
DE19756235A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
CA2347092A1 (fr) 1998-10-14 2000-04-20 Ortho-Mcneil Pharmaceutical, Inc. Cyclopropanes a disubstitution en position 1 et 2
GB9919588D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
WO2001055146A1 (fr) 2000-01-29 2001-08-02 Lg Chem Investment Ltd. INHIBITEURS DU FACTEUR Xa CONTENANT DES ARYLAMIDINES ET DES DERIVES, ET PROMEDICAMENTS OBTENUS A PARTIR DESDITS INHIBITEURS
AU2001268724B2 (en) 2000-06-29 2005-06-16 Abbott Laboratories Aryl phenycyclopropyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
DE10036184A1 (de) 2000-07-24 2002-02-14 Aventis Cropscience Gmbh Substituierte Sulfonylaminomethylbenzoesäure(derivate) und Verfahren zu ihrer Herstellung
CA2417507A1 (fr) 2000-08-21 2002-02-28 Pacific Corporation Nouveaux derives de thiourea et compositions pharmaceutiques renfermant ceux-ci
JP2004506714A (ja) * 2000-08-21 2004-03-04 パシフィック　コーポレーション 新規チオ尿素化合物及びこれを含有する薬学的組成物
GB0105895D0 (en) * 2001-03-09 2001-04-25 Smithkline Beecham Plc Novel compounds
WO2002100352A2 (fr) * 2001-06-12 2002-12-19 Merck & Co., Inc. Antagonistes du recepteur nr2b pour le traitement ou la prevention de migraines
EP1490043A4 (fr) 2002-03-26 2007-05-30 Merck & Co Inc Amides spirocycliques en tant que modulateurs du recepteur cannabinoide
AU2003265394A1 (en) 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors containing dimethyl-cyclobutane and methods of their synthesis and use
KR100556158B1 (ko) * 2002-10-17 2006-03-06 (주) 디지탈바이오텍 신규 엔-하이드록시 티오우레아, 우레아 및 아미드계화합물 및 이를 함유하는 약제학적 조성물
US7144881B2 (en) * 2002-11-22 2006-12-05 Bristol-Myers Squibb Company Arylcyclopropylcarboxylic amides as potassium channel openers
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
US20050004133A1 (en) 2003-06-05 2005-01-06 Makings Lewis R. Modulators of VR1 receptor
KR100707123B1 (ko) * 2003-07-02 2007-04-16 그뤼넨탈 게엠베하 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 4-(메틸설포닐아미노)페닐 동족체 및 이를함유하는 약학적 조성물
WO2005007614A1 (fr) * 2003-07-03 2005-01-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services 6011 Inhibiteurs d'oxydase de monoamine
WO2005051890A1 (fr) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Acides aminophenylcyclopropylcarboxyliques et leurs derives servant d'agonistes de gpr40
US7244735B2 (en) 2003-12-02 2007-07-17 Vertex Pharmaceuticals Inc. Heterocyclic protein kinase inhibitors and uses thereof
DE102005011056A1 (de) 2004-03-26 2005-10-13 Merck Patent Gmbh Fluorcyclopropanderivate
JP2005314407A (ja) 2004-03-31 2005-11-10 Nippon Nohyaku Co Ltd 新規なハロアルキルスルホンアニリド誘導体、除草剤及びその使用方法並びにその中間体
WO2006098554A1 (fr) 2005-03-16 2006-09-21 Amorepacific Corporation Nouveaux composes, isomere de ceux-ci ou sels pharmaceutiquement acceptables de ceux-ci en tant qu’antagonistes du recepteur vanilloide ; et composition pharmaceutique contenant ceux-ci

Also Published As

Publication number Publication date
NL1031385A1 (nl) 2006-09-20
ZA200707531B (en) 2008-10-29
NO20075312L (no) 2007-12-10
GT200600114A (es) 2006-10-25
CA2601508A1 (fr) 2006-09-21
DOP2006000063A (es) 2006-10-15
EA200701745A1 (ru) 2008-06-30
US20100035880A1 (en) 2010-02-11
EP1861359A1 (fr) 2007-12-05
EP1861359B1 (fr) 2012-11-14
CR9375A (es) 2008-01-29
MX2007011498A (es) 2007-10-11
CN101160285A (zh) 2008-04-09
US7622589B2 (en) 2009-11-24
KR20070103778A (ko) 2007-10-24
NL1031385C2 (nl) 2007-03-05
IL185546A0 (en) 2008-01-06
TNSN07349A1 (fr) 2008-12-31
JP2008535801A (ja) 2008-09-04
CA2601508C (fr) 2012-01-03
AR055878A1 (es) 2007-09-12
TW200716528A (en) 2007-05-01
JP4521463B2 (ja) 2010-08-11
AU2006224295A1 (en) 2006-09-21
WO2006097817A1 (fr) 2006-09-21
AP2007004157A0 (en) 2007-10-31
UY29421A1 (es) 2006-10-31
WO2006097817A9 (fr) 2006-12-07
BRPI0608436A2 (pt) 2009-12-29
KR100927915B1 (ko) 2009-11-19
AU2006224295A8 (en) 2009-08-27
US7915448B2 (en) 2011-03-29
PE20061150A1 (es) 2006-11-08
US20060211741A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
MA29335B1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
MA31865B1 (fr) Dérivés isoxazolo-pyridine
MA51620B1 (fr) Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques
MA52360B1 (fr) Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
MA31766B1 (fr) Composés organiques
MA27775A1 (fr) Composes organiques
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
MA28747B1 (fr) Dérivés de pyridine
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
MA29926B1 (fr) Derives de pyrazine
TW200505903A (en) CGRP receptor antagonists
MA30411B1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
EA200600048A1 (ru) Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
MA54386B1 (fr) Modulateurs de trex1
EA200901159A1 (ru) Производные 3-циано-4-(4-фенилпиперидин-1-ил)пиридин-2-она
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
MA30355B1 (fr) Derives d'azabicyclo [3. 1. 0] hexyle utilises comme modulateurs des recepteurs de la dopamine d3
ATE466860T1 (de) Cgrp-rezeptorantagonisten
MA27990A1 (fr) Derives de piperazine pour le traitement d'infections par le vih
EP1689713A4 (fr) Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak